To highlight the value of UM30-OSN in modeling APOL1-mediated kidney disease with an APOL1 (G1/G0) genotype, we examined how Interferon-γ (IFN-γ) affects UM30-OSN–derived podocytes and assessed whether the JAK1/JAK2 inhibitor Baricitinib can counteract IFN-γ–induced cellular responses. This evidence concerns the gene JAK1 and kidney disorder.